Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 265 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Patient Guide on Cancer Pain Management Now Available Also in French December 16, 2025 Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... July 23, 2020 Cancer Survivors Face High Rates of Housing Insecurity February 5, 2022 Rare Disease Day 2026: Advancing equity for people living with rare... February 27, 2026 Load more HOT NEWS Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... 2026 Heine H. Hansen Award Recipient Announced Turning the Life Sciences Vision into reality Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal...
